Cell Therapy Startups

LEAH Labs engineers gene-edited CAR-T cell therapies to treat cancer in pet dogs, with the goal of generating translational insights for human cancer therapy. The company uses proprietary gene editing and protein design to develop therapeutic treatments for companion animal oncology.

2 investors

Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.

2 investors

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Indee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.

1 investor

WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

1 investor